SPS
PRME icon

Susquehanna Portfolio Strategies’s Prime Medicine PRME Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-29,247
Closed -$150K – 462
2024
Q2 		$150K Sell
29,247
-87,640
-75% -$531K 0.01% 480
2024
Q1 		$818K Hold
116,887
– – 0.02% 497
2023
Q4 		$1.04M Buy
+116,887
New +$900K 0.02% 589

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Susquehanna Portfolio Strategies's PRME Position: Q3 2024 in Review

Susquehanna Portfolio Strategies sold out of Prime Medicine (PRME) in Q3 2024, closing a stake of 29,247 shares — an estimated $150K sold.

Susquehanna Portfolio Strategies first reported a position in PRME in Q4 2023 and held it in 3 quarters. The position peaked at $1.04M in Q4 2023. 116 funds tracked by Wall St. Rank hold PRME as of Q3 2024.

  • Susquehanna Portfolio Strategies reported no remaining Prime Medicine position as of Q3 2024 after selling out during the quarter.
  • Susquehanna Portfolio Strategies sold 29,247 Prime Medicine shares in Q3 2024, an estimated $150K.
  • Susquehanna Portfolio Strategies first reported a position in Prime Medicine in Q4 2023 and held it in 3 quarters.
  • Susquehanna Portfolio Strategies's Prime Medicine position peaked at $1.04M in Q4 2023.
  • 116 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2024.

Based on Susquehanna Portfolio Strategies's 13F filing for Q3 2024, filed 14 Nov 2024.